Varubi Dosage

Generic name: ROLAPITANT HYDROCHLORIDE 90mg
Dosage form: tablet
Drug class: NK1 receptor antagonists

Medically reviewed by Drugs.com. Last updated on Aug 9, 2023.

The recommended dosage of VARUBI in adults in combination with a 5-HT3 receptor antagonist and dexamethasone for the prevention of nausea and vomiting with emetogenic cancer chemotherapy is shown in Table 1. There is no drug interaction between rolapitant and dexamethasone, so no dosage adjustment for dexamethasone is required. Administer a dexamethasone dose of 20 mg on Day 1 [see Clinical Pharmacology (12.3)].

Administer VARUBI prior to the initiation of each chemotherapy cycle, but at no less than 2 week intervals.

Administer VARUBI without regards to meals.

Table 1: Recommended Dosing Regimen of VARUBI
	Day 1	Day 2	Day 3	Day 4
Prevention of Nausea and Vomiting Associated with Cisplatin-Based Highly Emetogenic Cancer Chemotherapy
VARUBI	180 mg as a single dose orally within 2 hours prior to initiation of chemotherapy	None
Dexamethasone	20 mg; 30 min prior to initiation of chemotherapy	8 mg twice daily	8 mg twice daily	8 mg twice daily
5-HT3 receptor antagonist	See the prescribing information for the co-administered 5-HT3 receptor antagonist for appropriate dosing information.	None
Prevention of Nausea and Vomiting Associated with Moderately Emetogenic Cancer Chemotherapy and Combinations of Anthracycline and Cyclophosphamide
VARUBI	180 mg as a single dose orally within 2 hours prior to initiation of chemotherapy	None
Dexamethasone	20 mg; 30 min prior to initiation of chemotherapy	None
5-HT3 receptor antagonist	See the prescribing information for the co-administered 5-HT3 receptor antagonist for appropriate dosing information.	See the prescribing information for the co-administered 5-HT3 receptor antagonist for appropriate dosing information.